EXACT Sciences Company Description
Guesstimates aren't good enough when diagnosing a deadly cancer, so EXACT Sciences aims for accuracy. The firm develops non-invasive tests for the early detection of colorectal cancer and precancerous lesions. Its products isolate DNA in stool samples, using its Effipure technology, then identify genetic mutations associated with cancer. Colorectal cancer is a common (and one of the deadliest) cancers, and EXACT believes its method is superior to existing diagnostic methods because it may be able to discern colorectal cancer in its early stages, when it is most treatable. However, facing several product development setbacks, the company is undergoing a strategic reorganization.
View the Comprehensive Company Description for EXACT Sciences
The Company Description provides a historical perspective of EXACT Sciences's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of EXACT Sciences's evolution in the marketplace.
